Read this company snapshot
Daily valuation snapshot
CytoMed Therapeutics Limited Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.89
- Market capitalization (USD)
- $10,622,068.12
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.99
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research GDTC in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research GDTC in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing GDTC with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $0.89 |
| Market capitalization (USD) | $10,622,068.12 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.99 |
No matching rows. Clear the filter to see all records.
Read GDTC's valuation metrics
Company size
CytoMed Therapeutics Limited Ordinary Shares's recorded market capitalization is $10,622,068.12. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
GDTC's recorded price-to-book ratio is 1.99. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research CytoMed Therapeutics Limited Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about GDTC. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow GDTC's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.